FY2029 EPS Estimates for CRBU Decreased by Analyst

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Management decreased their FY2029 earnings per share estimates for Caribou Biosciences in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of $16.83 per share for the year, down from their prior estimate of $16.92. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Other analysts have also issued research reports about the company. Bank of America lowered their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Citigroup lowered their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Buy” and an average target price of $10.33.

Caribou Biosciences Stock Performance

Shares of NASDAQ CRBU opened at $1.07 on Wednesday. The firm has a market capitalization of $96.89 million, a price-to-earnings ratio of -0.65 and a beta of 2.34. The stock has a 50 day moving average price of $1.41 and a 200 day moving average price of $1.80. Caribou Biosciences has a 52-week low of $1.01 and a 52-week high of $7.24.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%.

Hedge Funds Weigh In On Caribou Biosciences

A number of large investors have recently made changes to their positions in CRBU. Intech Investment Management LLC acquired a new position in shares of Caribou Biosciences during the third quarter worth $43,000. Charles Schwab Investment Management Inc. increased its position in shares of Caribou Biosciences by 19.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after purchasing an additional 118,325 shares in the last quarter. FMR LLC increased its position in shares of Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after purchasing an additional 109,606 shares in the last quarter. Walleye Capital LLC increased its position in shares of Caribou Biosciences by 45.9% during the third quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock worth $466,000 after purchasing an additional 74,799 shares in the last quarter. Finally, PFM Health Sciences LP increased its position in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares during the period. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.